FONT-SIZE Plus   Neg

OraSure And AbbVie To Co-promote OraQuick HCV Rapid Test In U.S. - Quick Facts

OraSure Technologies (OSUR) announced Wednesday that it has reached a Master Program Services and Co-Promotion Agreement with AbbVie (ABBV) under which AbbVie and OraSure will co-promote the Company's OraQuick HCV Rapid Test in the United States.

The product will be used to test individuals at-risk for hepatitis C (HCV). OraSure will be responsible for manufacturing and selling the product directly into all markets.

As per the agreement, OraSure has granted exclusive promotion rights to AbbVie for the OraQuick HCV test in certain markets and will provide certain additional services in support of HCV testing. In exchange for the exclusive rights granted to AbbVie, OraSure will receive up to $75 million in exclusivity payments over the term of the agreement, which runs through December 31, 2019.

In addition, upon achievement of certain performance-based milestones, OraSure will be eligible to receive additional payments annually over the life of the agreement. Further information regarding the agreement will be available in the Company's 8-K Report filed later today with the SEC.

As a result of the new co-promotion agreement announced, OraSure has updated its financial guidance to reflect the initial impact of this arrangement and is now projecting consolidated net revenues ranging from $26.0 to $26.5 million and a consolidated net loss of approximately $0.08 to $0.09 per share for the second quarter of 2014. Analysts polled by Thomson Reuters expect the company to report a loss of $0.09 per share and revenues of $25.39 million for the second-quarter. Analysts' estimates typically exclude special items.

OraSure said in May that it expected consolidated net revenues to range from $25.2 to $25.7 million and consolidated net loss of approximately $0.09 to $0.10 per share for the second quarter of 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Philips Electronics NV were gaining around 3 percent in the early morning trading in Amsterdam after the Dutch consumer electronics giant reported Monday a higher profit in its third quarter driven by margin strength with improved performance in its segments. Consolidated comparable sales growth was 2 percent, driven by 5 percent increase in HealthTech portfolio. AT&T announced a definitive agreement to purchase Time Warner in a stock-and-cash transaction valued at $107.50 per share. This purchase price implies a total equity value of $85.4 billion and a total transaction value of $108.7 billion, including Time Warner's net debt. AT&T expects the deal to close before year-end 2017. Chipmaker Qualcomm is reportedly in talks with NXP Semiconductor NV (NXPI) for a possible acquisition, reports said. According to Bloomberg, negotiations are on with a probable price of $110 t $120 per NXP share. The deal would value NXP at around $34.7 billion.
comments powered by Disqus
Follow RTT